

Methods: This phase 1 study evaluates safety, tolerability, pharmacokinetics/dynamics and anti-tumor effects of MT110 in pts with advanced solid tumors expressing EpCAM. A dose escalation with 3–6 pts per cohort is used to determine the maximum tolerated dose (MTD). Starting dose was 1 µg/d given as continuous i.v. infusion for 1 or more 28-day cycles.

Results: To date, a total of 14 pts (3 gastric, 9 CRC, 1 NSCLC, 1 SCLC; up to 7 previous chemotherapies) have been treated in 4 cohorts up to 10 µg/d. Overall, MT110 was very well tolerated with few clinical adverse events. All but 1 of the treated pts completed at least 4 wks of therapy. Besides initial lymphopenia, an increase in liver enzymes, up to grade 3/4, was the most frequent laboratory abnormality. These events were transient in nature and not found to impact on liver synthesis nor were any abnormal results seen in imaging (ultrasound, CT scan, and/or MRI of the liver). The increase in liver enzymes did not occur on re-exposure to MT110. Concomitant corticosteroids were found to mitigate increases in liver enzymes and further optimization of the treatment schedule is currently ongoing. As observed with blinatumomab, MT110 caused a rapid redistribution of lymphocytes shortly after infusion. Signs of T cell expansion/activation were seen in pts with clinical benefit after 4 wks. Disease stabilization according to RECIST was confirmed in 6 of 13 pts, lasting 12 wks in median. In one patient, a lung metastasis was resected 11 wks after initiation of MT110 treatment. Immunohistochemistry revealed tumor cell necrosis and a massive T cell infiltration as possible evidence of MT110 activity. None of the pts developed antibodies against MT110.

Conclusion: First signs of biological activity of MT110 in pts with advanced EpCAM-expressing tumors have been observed at clinically well tolerated doses. Optimization of the treatment schedule and evaluation of BiTE antibody MT110 at higher doses is currently ongoing.

References

- [1] Bargou R et al. (2008) *Science* 321:974.

1255

POSTER

Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor

J. de Bono¹, A.T. Brunetto¹, R. Kristeleit¹, A. Mais², B. Hauns², B. Hentsch². ¹The Royal Marsden NHS trust – Institute of Cancer Research, Department of Medicine, Sutton Surrey, United Kingdom; ²4SC AG, Medical Oncology, Planegg-Martinsried, Germany

Background: 4SC-201 is a new, specific, potent, pan-HDAC inhibitor under evaluation as mono or combination therapy for solid and haematological malignancies.

Methods: Preclinical studies of anti-cancer activity of 4SC-201 alone or in combination with other cancer drugs in cell lines and in xenograft models were performed. In a First-in-Man (FIM) study, patients (pts) with advanced refractory solid tumours were dosed once daily, d1–5, in a 14-day cycle in sequential cohorts. Objectives included determination of safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose and anti-cancer activity.

Results: In preclinical studies 4SC-201 demonstrated potent activity across a broad range of tumour cell lines originated from different cancers. Xenograft studies revealed strong dose-dependent anti-tumour activity and good tolerability. 4SC-201 enhanced the anti-tumour activity of a variety of approved cancer drugs when tested in combination. In a FIM study, 18 pts were treated at dose levels of 100 mg, 200 mg, 400 mg, 600 mg (3 pts each) and 800 mg (6 pts). Grade 3 DLT of nausea and vomiting occurred in 1 pt dosed at 800 mg. Most common adverse events included nausea, vomiting and fatigue. 8 of 9 pts treated at the two highest dose levels had stable disease during the main phase of the study (4 cycles). A patient with metastatic thymoma (minor response) continued treatment until cycle 18 and stopped without evidence of progressive disease. Another patient with liposarcoma remains on treatment for over a year. Following single oral administration high plasma exposure of 4SC-201 was obtained indicating good bioavailability with a dose-proportional PK profile and low inter-individual variability for all dose levels. Biomarker assays revealed that HDAC inhibition in PBMC ranged from 50 to 100% and was dose-dependent.

Conclusions: In summary, preclinical studies testing 4SC-201 alone or in combination with several cancer drugs showed substantial synergistic anti-tumour activity. Phase I data confirmed the favorable oral drug profile and good tolerability of 4SC-201. Efficient target modulation and anti-tumour activity were observed. Consequently, phase II development will be initiated aiming for clinical proof-of-concept in specific tumour indications, including combination studies with e.g. STIs such as sorafenib or chemotherapeutic agents.

1256

POSTER

Phase I trial of oral Deforolimus in combination with Bevacizumab in patients with advanced solid tumours

J. Nemunaitis¹, H.S. Hochster², S. Lustgarten³, C.D. Turner⁴, F. Haluska⁵, M.M. Mita⁶. ¹Mary Crowley Cancer Research Center/Sammons Cancer Center, Director, Dallas, USA; ²NYU Cancer Institute, Department of Medicine, New York, USA; ³ARIAD Pharmaceuticals Inc., Biostatistics, Cambridge, USA; ⁴ARIAD Pharmaceuticals Inc., Cambridge, USA; ⁵ARIAD Pharmaceuticals Inc., Clinical Research, Cambridge, USA; ⁶Cancer Therapy and Research Center, San Antonio, USA

Background: Deforolimus (DF) is a unique inhibitor of mammalian target of rapamycin (mTOR). One of mTOR's many functions is to regulate vascular endothelial growth factor (VEGF) secretion and VEGF receptor (VEGFR) signaling in endothelial target cells. Combination of bevacizumab (BV), a humanized monoclonal antibody that inhibits VEGF, with DF would be expected to diminish VEGF production and VEGFR signaling, and offer a promising therapeutic approach. The goal of the study was to identify an optimal phase 2 dose of DF combined with each of the two approved BV regimens.

Methods: Three dose combinations were tested in this phase 1, dose-escalation design in adult patients with advanced solid cancers (Clinical Trials ID: NCT00781846). The 3 dose combinations were: Cohort 1, DF 30 mg PO daily for 5 days/week (QD×5/wk) with BV 10 mg/kg IV every 2 weeks (4 wk cycles); Cohort 2a: DF 40 mg PO QD×5/wk and BV 10 mg/kg IV Q2 wks (4 wk cycles); and Cohort 2b: DF 40 mg PO QD×5/wk and BV 15 mg/kg IV Q3 wks (3 wk cycles). DLTs were protocol-defined events related to study drug that occurred during cycle 1.

Results: Seventeen patients (10F, 7M) were enrolled and treated; 16 were evaluable for DLTs (3 in Cohort 1; 6 in Cohort 2a; 7 in Cohort 2b). Median age was 60 years (range 24–72). Patients had 12 solid tumor types: 3 had ovarian carcinoma, 2 leiomyosarcoma, 2 pancreatic cancer, 2 colorectal carcinoma, 2 uterine carcinoma, and 6 had other distinct tumor types. No DLTs were noted in the 3 cohorts. One patient had 2 SAEs (G2 abdominal wall abscess and a G2 colonic fistula) related to BV per the investigator's assessment. Ten patients experienced treatment related AEs. The most common AEs were stomatitis, mucosal inflammation, neutropenia, thrombocytopenia, proteinuria, and headache. In this heavily pre-treated population, the median duration of treatment is currently 7 wks (range 2.3–24 wks). Six patients have discontinued treatment (4 for PD and 2 for unrelated SAEs) and 11 remain on treatment. Two patients have had stable disease for more than 4 months (1 patient with pancreatic cancer had a 13% reduction in tumor for more than 6 months and a patient with ovarian carcinoma that has been stable for 4+ months).

Conclusions: DF 40 mg QD×5/wk combined with two approved dosages and schedules (10 mg/kg q2 wks & 15 mg/kg q3 wks) of BV is feasible, well tolerated, and shows potential anti-tumor activity. The combination of DF/BV warrants further investigation in phase 2 trials.

1257

POSTER

Retrospective analysis of unplanned hospital admissions: an early surrogate indicator of patient (pt) attrition in phase-I trials

D. Olmos¹, A. Brunetto¹, J. Ang¹, D. Tan¹, S. Sandhu¹, R. Kristeleit¹, M. Lokelma¹, M. Forster¹, R. Molife¹, S. Kaye¹. ¹The Royal Marsden NHS Trust, Drug Development Unit, Sutton London, United Kingdom

Background: We have previously reported a high Royal Marsden Hospital (RMH) prognostic score (RPS) of 2–3 predicts 90-day mortality and reduced overall survival (Arkenau et al BJC & EJC 2008). In this study, we explored the significance of unplanned hospital admissions (UHA) as a potential surrogate indicator of poor clinical outcome.

Methods: All pts admitted to RMH Phase I Unit, UK, during 2-month intervals over 3 consecutive years were included in this analysis (2005–2007). We collated pt baseline characteristics, demographic and laboratory profiles, reasons for hospital admissions and relevant clinical trial data.

Results: A total of 172 pts accounting for 310 admissions were seen on the Phase I unit during the stipulated time periods (amounting to 6 months in total). Median age: 61 years (range: 19–84); male to female admissions ratio 1.3:1. Pts were on trials of single-agent targeted therapies (69%), cytotoxic combinations (26%), vaccine/viruses (3%) and hormonal modulation (2%). Reasons for planned admissions (n=246) included treatment commencement, PK/PD sampling, paired pre/post treatment biopsies and insertion of central lines. 20.6% (64/310) of overall admissions were unplanned: 50 (78%) were due to disease-associated symptoms/complications and 14 (22%) treatment-related toxicities (TRT). 71% of pts with TRT were on cytotoxic combination trials. Median duration of UHA was 2 days (range: 1–20) and there was no relation between length of stay and predicted outcome. 78% of pts in the UHA cohort had a high RPS of 2–3 (i.e. poor outcome) vs 43% in patients whose admission was

planned ($p=0.001$). Of pts who required UHA, only 27% resumed their trial drug after recovery. The main statistically significant risk factors for UHA include >2 metastatic sites, (RR 2.6 [1.64–4.38], $p=0.001$), poor performance status (RR 2.47 [1.48–3.72] $p=0.003$), low albumin (RR 2.17 [1.36–3.52] $p=0.001$) and cytotoxic combination trials (RR 1.7 [1.09–2.86] $p=0.025$).

Conclusions: Unplanned admissions constitute 20.6% of Phase I inpatients, with the majority being disease rather than treatment-related. Regardless of length of stay, UHA portend poor outcomes for patients who are on treatment, with a risk profile underscoring the importance of pt and trial selection.

1258

POSTER

Changing perceptions of oncologists referring advanced colorectal (ACRC) patients (pts) to phase 1 trials: an evidence based approach

A.T. Brunetto¹, D.S.W. Tan¹, D. Olmos¹, T. Yap¹, S. Frentzas¹, S. Sandhu¹, K. Denholm¹, B. Ayite¹, J. de Bono¹, S. Kaye¹. ¹Institute Cancer Research, Drug Development Unit, London, United Kingdom

Introduction: After failure of conventional treatment pts with ACRC who remain well may receive phase 1 therapy. Pts rely on referring physicians opinion when considering treatment and a change in perception may increase number of referrals.

Methods: Analyze the outcome for 78 ACRC pts treated in 23 phase I trials at the Royal Marsden Hospital (RMH), between Jan 04–08. Apply newly developed RMH prognostic score (0–3, comprising high LDH, albumin <35 mg/dl and ≥ 2 number of metastatic sites; In addition, survey 64 colorectal oncologists who referred pts to our unit aiming to understand the reasons for referral and knowledge regarding experimental therapy. Describe whether after reading audit results their approach to phase 1 changed.

Results: *Audit:* Median age: 62 yrs [range (r): 26–79]. PFS and OS were 8.6 (95% CI: 6.4–10.7) and 29.1 weeks (95% CI: 15.7–42.5), respectively. 28.8 and 8.2% of the pts were assessed as having SD at 3 and 6 months, respectively. In the multivariate analysis, a high RMH prognostic score (2–3) was associated with poor OS [HR: 1.42 (1.09–1.85), $p=0.007$]; median OS was 19.4 weeks (95% CI 11.7–27.1) compared to 47.4 weeks for those pts with RMH prognosis score of 0–1 (95% CI 41.3–53.6, $p=0.029$).

Survey: 28/64 (44%) questionnaires were returned from medical and clinical oncologists (14/14). The median length of oncology experience was 10 yrs (r: 2–25); 64% had previous phase 1 experience and $>85\%$ were familiar with logistics and eligibility criteria. The most common reason for referral was lack of treatment options (64%); and the main reason for referral to our unit was proximity to pts (32%) and known centre of excellence (29%). The most common characteristic analyzed in pts before referral was performance status (93%). Median time spent with pts to discuss phase 1 was 10 min (r: 5–45) and possibility of any clinical benefit (43%) the main point. The median predicted PFS and OS was 2 (r: 2–4) and 5 (r: 4–8) months, respectively. 39% predicted that the prognostic factors in RMH score would be associated with outcome. 68% felt the audit results met their expectations although 42% would change their approach in some way. Moreover 21% would increase the number of referrals and 81% would be keen to answer similar questionnaires in the future.

Conclusion: Colorectal oncologists have a good knowledge regarding general outcomes of phase 1 trials in ACRC. The most common reason for referral was lack of treatment options, 42% of oncologist surveyed would change their approach in some way after reading audit results and 1/5 would increase their number of referrals.

1259

POSTER

Trabedersen (AP 12009) in the treatment of pancreatic carcinoma and other malignant tumors: interim results of the Phase I/II study

H. Oettle¹, A. Hilbig¹, T. Seufferlein², T. Luger³, R.M. Schmid⁴, G. Von Wichert⁵, H. Heinrichs⁶, K.H. Schlöglensiepen⁶. ¹Universitätsmedizin Berlin Charité, Campus Virchow-Klinikum, Berlin, Germany; ²Universitätsklinikum Halle (Saale), Innere Medizin, Halle (Saale), Germany; ³Universitätsklinik Münster Klinik und Poliklinik für Hautkrankheiten, Klinisches Zentrum für innovative Dermatologie, Münster, Germany; ⁴II. Medizinische Klinik und Poliklinik des Klinikums rechts der Isar der Technischen Universität München, Gastroenterologie, München, Germany; ⁵Universitätsklinikum Ulm, Innere Medizin I, Ulm, Germany; ⁶Antisense Pharma, Clinical Research, Regensburg, Germany

Background: TGF- $\beta 2$ stimulates metastasis of various malignant tumors and suppresses antitumor responses of the immune system.

Trabedersen (AP 12009) is a TGF- $\beta 2$ -specific antisense oligonucleotide. Trabedersen was safe and effective in high-grade glioma patients, as shown in a randomized, active-controlled Phase IIb study. In patients

with anaplastic astrocytoma the median survival benefit was 17.4 months compared to standard therapy. A Phase III study (SAPPHIRE) is ongoing. In this study we evaluate the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, and efficacy of intravenous treatment with trabedersen in patients with other advanced tumors.

Methods: In the open label, multicenter, dose-escalation Phase I/II study (AP 12009-P001; NCT00844064; sponsor: Antisense Pharma, GER), 33 patients with advanced pancreatic carcinoma (stage IVA/IVB, N=23), malignant melanoma (stage III/IV, N=5), or colorectal carcinoma (stage III/IV, N=5) were enrolled in several cohorts. Patients were treated intravenously with trabedersen as 2nd to 4th-line therapy as monotherapy with escalating doses in two treatment schedules (1st schedule: 7 d on, 7 d off; 2nd schedule: 4 d on, 10 d off; up to 10 cycles).

Results: Treatment with trabedersen was safe and well tolerated. Within the 1st treatment schedule MTD was established at 160 mg/m²/d, after NCI-CTC grade 3 dose limiting toxicities (2 self-limiting and transient thrombocytopenias, 1 exanthema) had occurred. One patient with metastatic pancreatic carcinoma had a complete response of liver metastasis and is alive 41 months after enrollment.

In the 2nd treatment schedule dose escalation was stopped after the 4th cohort, before MTD had been reached, as a dose was identified, which was well tolerated and had very promising efficacy data. The median overall survival for patients with pancreatic carcinoma treated with the defined dose (N=5) was 13.4 months. One patient of this cohort shows stable disease 14.8 months after enrollment in the study.

First efficacy results were also seen in advanced malignant melanoma, as one patient treated within the 1st schedule survived 13.8 months.

Conclusions: Trabedersen is a promising treatment option for patients with advanced solid tumors. Currently the study continues with recruitment of 24 patients with either pancreatic carcinoma or malignant melanoma.

1260

POSTER

Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

P. Schöffski¹, J.Y. Blay², J. De Greve³, E. Brain⁴, J.P. Machiels⁵, J.C. Soria⁶, S. Sleijfer⁷, G. Munzert⁸, J. Rapin⁹, D. Lacombe⁹. ¹U.Z. Gasthuisberg, Department of General Medical Oncology, Leuven, Belgium; ²Centre Leon Berard, Department de Medecine, Lyon, France; ³Universitair Ziekenhuis Brussel, Department of Medical Oncology, Brussels, Belgium; ⁴Centre Rene Huguenin, Medical Oncology, Saint-Cloud, France; ⁵Cliniques Universitaires St. Luc, Medical Oncology Unit, Brussels, Belgium; ⁶Institut Gustave Roussy, Department of Medicine, Villejuif, France; ⁷Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, The Netherlands; ⁸Boehringer Ingelheim, Clinical Research, Biberach, Germany; ⁹European Organisation for Research and Treatment of Cancer, Headquarters, Brussels, Belgium

Background: BI-2536 inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division. EORTC 90061 assessed the efficacy and safety of BI-2536 in five different cohorts of patients with advanced solid tumors.

Materials and Methods: Patients with head and neck cancer (no prior chemotherapy [CTX] for recurrent or metastatic disease), breast cancer (after a maximum of two lines of prior CTX), ovarian cancer (progressive within 6 months after completion of platinum based CTX), soft tissue sarcoma (after no more than one combination or two single agent CTX) or CTX-naïve melanoma with documented progression, adequate performance status, and good organ function were eligible. BI-2536 was given by i.v. infusion of 200 mg on day 1 every three weeks until intolerance or disease progression. Primary end point was the objective response rate (OR) according to RECIST. Secondary end points included safety (CTCAE version 3.0) and overall survival. For each tumour type a Simon optimal 2-stage design for OR was applied (type 1 and type 2 error 10%, null hypothesis 5% OR, alternative hypothesis 20% OR; stage 1 and 2: 12 and an additional 25 patients, respectively). If no OR were observed among the first 12 patients the tumour type was closed for further accrual.

Results: 76 patients were included between 07/2007 and 04/2008. Five patients never received study drug because of ineligibility. The median number of cycles was 2 in all organ types, except for a median of 4 in ovarian cancer. Main drug-related toxicities were febrile neutropenia (gr 3/4: 19.7%), and fatigue (gr 2/3: 31.0%). Most frequent grade 3–4 toxicities were neutropenia (81.6%), thrombocytopenia (19.7%) and anemia (15.5%). Most frequent non-hematologic toxicities were fatigue (gr 2/3: 31.0%), alopecia (26.7%), anorexia (14.1%), and nausea (12.7%), mostly grade 1–2. An